Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug...
DUBLIN, Feb. 18, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Focal Catheters are the first and only ablation catheters approved by the U.S. Food and Drug Administration (FDA) to treat the growing prevalence of pediatric Atrioventricular Nodal Reentrant Tachycardia (AVNRT).
AVNRT is the most common form of supraventricular tachycardia (SVT), and is a life-threatening abnormal heart rhythm, with 89,000 cases each year and growing. Nearly 35% of AVNRT cases occur in pediatrics, or, children under the age of 18. Due to an abnormal circuit within the heart's conduction system, AVNRT causes a very rapid heart rhythm, and if left untreated, can affect the heart's ability to pump normally, leading to palpitations, lightheadedness, and syncope.
Catheter ablation is a first-line therapy for treatment of AVNRT. The Freezor and Freezor Xtra Catheters are flexible, single-use devices used to freeze cardiac tissue and block unnecessary electrical signals within the heart. The Freezor family enables safe and effective focal cryoablation therapy and has treated more than 140,000 patients across 67 countries. Cryoablation can reduce the risk of permanent AV block, a complication of AVNRT procedures performed with radiofrequency (RF) ablations that results in the partial or complete interruption of the heart's electrical signals, which dangerously disrupts heart rhythm.
"There are very few devices approved to treat medically complex pediatric cardiology patients today," said Bryan C. Cannon, M.D., professor of pediatrics and past president of the Pediatric & Congenital Electrophysiology Society (PACES), the largest organization in the world for pediatric rhythm specialty doctors. "With an FDA indication expansion, the Freezor and Freezor Xtra cardiac cryoablation catheters allow even the youngest of cardiology patients access to a safe, life-enhancing technology that will help advance cardiac care for AVNRT."
The indication expansion approval is supported by results from ICY-AVNRT and multiple pediatric randomized, multi-center studies that demonstrated the safety and effectiveness of the treatment of AVNRT using the Freezor and Freezor Xtra cardiac cryoablation catheters. ICY-AVNRT data reported acute procedural success of 95% with no reports of permanent pacemaker due to complete AV block.1 The larger body of evidence, including a total of sixteen studies, also observed high efficacy rates and low adverse events.2-17
The Freezor cardiac cryoablation catheter was first commercially available in the U.S. for adult use of AVNRT in 2003, followed by the Freezor Xtra cardiac cryoablation catheter in 2016. The Freezor family of cryoablation catheters also includes the Freezor MAX cardiac cryoablation catheter, which is approved for use in conjunction with the Arctic Front™ Advance cryoballoon for the treatment of atrial fibrillation (AF).
"We're proud of our work with PACES and FDA in this first-of-its-kind, multi-stakeholder initiative to address a critical patient population," said Rebecca Seidel, president of the Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "The shared commitment to collaborate and grow this therapy's unique position to treat AVNRT patients demonstrates our confidence in the proven safety and efficacy of our cryoablation technology."
Medtronic has pioneered cryoablation technology, with an industry-leading and extensive body of evidence, including proven safety and efficacy in treating AF and AVNRT. To date, more than one million patients have been treated with Medtronic cryoablation therapy worldwide.
In collaboration with leading clinicians, researchers, and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services of the highest quality that deliver clinical and economic value to healthcare consumers and providers around the world.
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
1 Wells P, Dubuc M, Klein GJ, et al. Intracardiac ablation for atrioventricular nodal reentry tachycardia using a 6 mm distal electrode cryoablation catheter: Prospective, multicenter, North American study (ICY-AVNRT STUDY). J Cardiovasc Electrophysiol. 2018;29:167–176.
2 Avari J.N., Jay K.S., Rhee E.K.. Experience and results during transition from radiofrequency ablation to cryoablation for treatment of pediatric atrioventricular nodal reentrant tachycardia PACE Pacing Clin. Electrophysiol. 2008;31:454-460.
3 Beach C., Beerman L., Mazzocco S., et al. Use of three-dimensional mapping in young patients decreases radiation exposure even without a goal of zero fluoroscopy. Cardiology in the Young. 2016; 26:1297-1302. (epub 2015).
4 Chanani, NK, Chiesa, NA, Dubin, et al. Cryoablation for atrioventricular nodal reentrant tachycardia in Young patients: predictors of recurrence. Pacing Clin Electrophysiol. 2008; 31: 1152-1159.
5 Cokkinakis C., Avramidis D., Alexopoulos C., et al. Cryoablation of atrioventricular nodal reentrant tachycardia in children and adolescents: Improved long-term outcomes with increasing experience Hell. J. Cardiol. 2013;54:186-191.
6 Drago F., Placidi S., Righi D., et al. Cryoablation of AVNRT in children and adolescents: Early intervention leads to a better outcome J. Cardiovasc. Electrophysiol. 2014;25:398-403.
7 Drago F., Righi D., Placidi S., et al. Cryoablation of right-sided accessory pathways in children: Report of efficacy and safety after 10-year experience and follow-up Europace 2013;15:1651-1656.
8 Drago F., Russo M.S., Silvetti M.S., et al. Cryoablation of typical atrioventricular nodal reentrant tachycardia in children: Six years' experience and follow-up in a single center PACE Pacing Clin. Electrophysiol. 2010;33:475-481.
9 Gist K.M., Bockoven J.R., Lane J., et al. Acute success of cryoablation of left-sided accessory pathways: A single institution study. Journal of Cardiovascular Electrophysiology. 2009; 20(6):637-642.
10 Gist K., Tigges C., Smith G., et al. Learning curve for zero-fluoroscopy catheter ablation of avnrt: Early versus late experience PACE Pacing Clin. Electrophysiol. 2011;34:264-268.
11 Papagiannis J., Papadopoulou K., Rammos S., et al. Cryoablation versus radiofrequency ablation for atrioventricular nodal reentrant tachycardia in children: Long-term results Hell. J. Cardiol. 2010;51:122-126.
12 Pieragnoli P., Paoletti Perini A., Checchi L., et al. Cryoablation of typical AVNRT: Younger age and administration of bonus ablation favor long-term success. Heart Rhythm. 2015;12:2125–2131.
13 Qureshi M.Y., Ratnasamy C., Sokoloski M., et al. Low recurrence rate in treating atrioventricular nodal reentrant tachycardia with triple freeze-thaw cycles PACE Pacing Clin. Electrophysiol. 2013;36:279-285.
14 Reents T., Springer B., Ammar S., et al. Long-term follow-up after cryoablation for adolescent atrioventricular nodal reentrant tachycardia: Recurrence is not predictable. Europace. 2012; 14(11):1629-1633.
15 Russo M.S., Drago F., Silvetti M.S., et al. Comparison of cryoablation with 3D mapping versus conventional mapping for the treatment of atrioventricular re-entrant tachycardia and right-sided paraseptal accessory pathways . Cardiology in the Young. 2016; 26:931-940. (epub 2015).
16 Scaglione M., Ebrille E., Caponi D., et al. Single center experience of fluoroless AVNRT ablation guided by electroanatomic reconstruction in children and adolescents PACE Pacing Clin. Electrophysiol. 2013;36:1460-1467.
17 Young ML, Niu J. Using coronary sinus ostium as the reference for the slow pathway ablation of atrioventricular nodal reentrant tachycardia in children. Journal of Arrythmia. 2020;36(4):712-719.
SOURCE Medtronic plc